Becton Dickinson and (BDX) Given a $260.00 Price Target by Deutsche Bank Analysts

Deutsche Bank set a $260.00 target price on Becton Dickinson and (NYSE:BDX) in a research note published on Friday, December 29th, Marketbeat Ratings reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

A number of other research analysts have also commented on BDX. Piper Jaffray Companies reaffirmed a buy rating and set a $213.00 price target on shares of Becton Dickinson and in a research report on Tuesday, September 12th. Wells Fargo & Co initiated coverage on Becton Dickinson and in a research report on Friday, September 22nd. They set an outperform rating and a $225.00 price target for the company. Zacks Investment Research downgraded Becton Dickinson and from a hold rating to a sell rating in a report on Monday, October 9th. Royal Bank of Canada reiterated a hold rating and set a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Finally, Morgan Stanley upped their target price on Becton Dickinson and from $205.00 to $245.00 and gave the stock an equal weight rating in a report on Friday, November 3rd. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $230.20.

Becton Dickinson and (BDX) opened at $227.71 on Friday. Becton Dickinson and has a fifty-two week low of $169.19 and a fifty-two week high of $229.68. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The stock has a market capitalization of $52,240.00, a PE ratio of 48.97, a PEG ratio of 1.70 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same quarter in the previous year, the company posted $2.12 EPS. Becton Dickinson and’s revenue for the quarter was down 2.0% on a year-over-year basis. research analysts anticipate that Becton Dickinson and will post 10.89 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 29th. Investors of record on Friday, December 8th were issued a $0.75 dividend. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date of this dividend was Thursday, December 7th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 64.52%.

A number of large investors have recently bought and sold shares of BDX. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Becton Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares in the last quarter. Harfst & Associates Inc. grew its position in shares of Becton Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd grew its position in shares of Becton Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after purchasing an additional 338 shares in the last quarter. Acrospire Investment Management LLC grew its position in shares of Becton Dickinson and by 259.7% during the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after purchasing an additional 600 shares in the last quarter. Finally, Valeo Financial Advisors LLC purchased a new position in shares of Becton Dickinson and during the third quarter valued at about $191,000. 75.53% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Becton Dickinson and (BDX) Given a $260.00 Price Target by Deutsche Bank Analysts” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://ledgergazette.com/2018/01/13/becton-dickinson-and-bdx-given-a-260-00-price-target-by-deutsche-bank-analysts.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply